Freestone S, Lennard M S, Silas J H, Ramsay L E
Postgrad Med J. 1983;59 Suppl 3:36-7.
The beta-blocking activity of two slow-release formulations of metoprolol was compared to conventional metoprolol and atenolol which were each given once daily for one week to 8 healthy volunteers in a balanced crossover study. Plasma levels of metoprolol were also measured. Only metoprolol SA (Astra) produced plasma concentrations significantly higher than those for conventional metoprolol 24 hours after dosing. Mean reduction in exercise tachycardia at 24 hours after dosing was significantly greater with atenolol and metoprolol SA than with metoprolol SR and conventional metoprolol. Beta-adrenoceptor blocking activity at 24 hr was more variable with all formulations of metoprolol than with atenolol, which was explained by differences in metoprolol metabolism. Subjects who were found to be "poor metabolizers" when tested with debrisoquine had much greater bioavailability, half-life and response to metoprolol. These subjects had maintained beta-blocking activity at 24 hr following metoprolol whereas extensive metabolizers did not, even with sustained-release formulations. The response to atenolol did not depend on oxidation phenotype.
在一项平衡交叉研究中,将两种美托洛尔缓释制剂的β受体阻滞活性与常规美托洛尔和阿替洛尔进行比较,这三种药物均每日给药一次,共给药一周,受试对象为8名健康志愿者。同时还测定了美托洛尔的血浆水平。仅美托洛尔缓释片(阿斯利康公司生产)在给药24小时后产生的血浆浓度显著高于常规美托洛尔。给药24小时后,阿替洛尔和美托洛尔缓释片使运动性心动过速的平均降低幅度显著大于美托洛尔缓释胶囊和常规美托洛尔。与阿替洛尔相比,所有美托洛尔制剂在24小时时的β肾上腺素能受体阻滞活性变化更大,这可以用美托洛尔代谢的差异来解释。在用异喹胍测试时被发现为“代谢缓慢者”的受试者,其美托洛尔的生物利用度、半衰期和反应性更高。这些受试者在服用美托洛尔后24小时仍保持β受体阻滞活性,而即使使用缓释制剂,广泛代谢者也没有。对阿替洛尔的反应不取决于氧化表型。